Trialstirzepatidemayo clinicmenopauseobesity

Mayo Clinic opens phase 4 tirzepatide trial in postmenopausal hot flashes

The pilot study, NCT07218445, also tracks measures of biological aging in postmenopausal women with obesity and began enrolling in April.

By Priya Raman · Science Reporter

Oct 6 08:00 ETSource: ClinicalTrials.gov

The wire

01Mayo Clinic registered NCT07218445, a recruiting phase 4 pilot testing tirzepatide's effect on menopausal vasomotor symptoms and biological aging markers in postmenopausal women with obesity, started April 8, 2026.
02Vasomotor symptoms are a new indication direction for incretins, relevant to clinicians already fielding off-label menopause questions from patients on tirzepatide.
03It is a single-center pilot with no posted enrollment target or results in the registry entry, so no efficacy conclusions can be drawn yet.

From the source

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
NCT07218445 · PHASE4 · RECRUITING · Sponsor: Mayo Clinic · Conditions: Obesity, Menopause Hot Flashes.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07218445